Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has earned a consensus recommendation of “Buy” from the twenty-six analysts that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and nineteen have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $179.39.

A number of analysts have recently issued reports on the stock. Stifel Nicolaus reaffirmed a “buy” rating and set a $190.00 price objective on shares of Jazz Pharmaceuticals PLC in a report on Thursday. Cowen and Company reaffirmed an “outperform” rating and set a $190.00 price objective on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, August 9th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $177.00 price objective (down from $178.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 10th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $177.00 price objective on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 10th. Finally, Janney Montgomery Scott reaffirmed a “buy” rating and set a $192.00 price objective (up from $180.00) on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, August 9th.

Jazz Pharmaceuticals PLC (JAZZ) opened at 138.46 on Friday. Jazz Pharmaceuticals PLC has a one year low of $95.80 and a one year high of $163.75. The firm has a market capitalization of $8.32 billion, a P/E ratio of 21.33 and a beta of 1.05. The stock’s 50 day moving average is $147.15 and its 200 day moving average is $151.23.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.85 by ($0.13). Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The company had revenue of $394.39 million for the quarter, compared to the consensus estimate of $410.83 million. During the same period in the prior year, the firm posted $2.67 earnings per share. The business’s revenue was up 3.5% on a year-over-year basis. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post $10.88 earnings per share for the current fiscal year.

In related news, Director Paul L. Berns sold 662 shares of the business’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $142.37, for a total transaction of $94,248.94. Following the transaction, the director now owns 6,599 shares in the company, valued at $939,499.63. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Paul Treacy sold 1,304 shares of the business’s stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $143.32, for a total transaction of $186,889.28. The disclosure for this sale can be found here. Insiders sold 4,517 shares of company stock worth $665,623 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC increased its position in shares of Jazz Pharmaceuticals PLC by 11.4% during the second quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock valued at $1,289,159,000 after buying an additional 849,348 shares during the period. Vanguard Group Inc. increased its position in shares of Jazz Pharmaceuticals PLC by 3.4% during the second quarter. Vanguard Group Inc. now owns 4,677,223 shares of the specialty pharmaceutical company’s stock valued at $727,308,000 after buying an additional 153,908 shares during the period. BlackRock Inc. increased its position in shares of Jazz Pharmaceuticals PLC by 3,163.9% during the first quarter. BlackRock Inc. now owns 3,215,159 shares of the specialty pharmaceutical company’s stock valued at $466,615,000 after buying an additional 3,116,652 shares during the period. JPMorgan Chase & Co. increased its position in shares of Jazz Pharmaceuticals PLC by 41.2% during the second quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock valued at $218,540,000 after buying an additional 410,031 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Jazz Pharmaceuticals PLC by 3.5% during the second quarter. Renaissance Technologies LLC now owns 1,201,500 shares of the specialty pharmaceutical company’s stock valued at $186,833,000 after buying an additional 40,537 shares during the period. Institutional investors own 87.91% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/27/jazz-pharmaceuticals-plc-jazz-given-average-rating-of-buy-by-analysts-2.html.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.